Skip to content

aTyr Pharma ATYR Restricted Cash

Restricted Cash at other companies

Merck & Co. logo
Merck & Co.MRK
$71M-31.1%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$1.53M+48.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$57K
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$102K-53.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.23M+4,203%
LQD
Liquidia CorporationLQDA
$3.5M

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's restricted cash?
aTyr Pharma (ATYR) reported restricted cash of $1.81M in Q1 2026.
How has aTyr Pharma's restricted cash changed year-over-year?
aTyr Pharma's restricted cash decreased by 25.8% year-over-year, from $2.43M to $1.81M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.